Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977327 | 0.94 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL583721 | 0.83 | CYP1A2 (0.58) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL5442144 | 0.81 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL6064058 | 0.81 | CYP1A2 (0.61) | SIGMAR1KMT2A | |
| Hydrochloric Acid SCHEMBL8017800 | 0.81 | CYP1A2 (0.56) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL28792545 | 0.80 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27751270 | 0.79 | CYP2D6 (0.49) | SLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL10454919 | 0.79 | KCNA5 (0.49) | SIGMAR1MEN1KMT2A | |
| SCHEMBL6618701 | 0.79 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL8773823 | 0.79 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2586778-A2 | Pyridazinone derivatives useful as glucan synthase inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2137179-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | SLC6A4 4582/4885SLC6A2 4734/4885SLC6A3 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.